Morgan Stanley’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,684
| Closed | -$387 | – | 8278 |
|
|
2024
Q4 | $387 | Sell |
1,684
-708
| -30% | -$850 | ﹤0.01% | 7367 |
|
|
2024
Q3 | $5.14K | Sell |
2,392
-7,307
| -75% | -$26.2K | ﹤0.01% | 6912 |
|
|
2024
Q2 | $50K | Sell |
9,699
-7,762
| -44% | -$40.8K | ﹤0.01% | 6169 |
|
|
2024
Q1 | $93.4K | Buy |
17,461
+14,223
| +439% | +$98.3K | ﹤0.01% | 6016 |
|
|
2023
Q4 | $25.2K | Sell |
3,238
-1,460
| -31% | -$5K | ﹤0.01% | 6579 |
|
|
2023
Q3 | $18.6K | Sell |
4,698
-1,876
| -29% | -$7.02K | ﹤0.01% | 6513 |
|
|
2023
Q2 | $20.7K | Sell |
6,574
-6,417
| -49% | -$20.6K | ﹤0.01% | 6554 |
|
|
2023
Q1 | $34.7K | Buy |
12,991
+6,149
| +90% | +$23.8K | ﹤0.01% | 6414 |
|
|
2022
Q4 | $24.6K | Sell |
6,842
-2,827
| -29% | -$12.3K | ﹤0.01% | 6598 |
|
|
2022
Q3 | $62K | Sell |
9,669
-233
| -2% | -$1.89K | ﹤0.01% | 6309 |
|
|
2022
Q2 | $95K | Buy |
9,902
+1,844
| +23% | +$17.3K | ﹤0.01% | 6303 |
|
|
2022
Q1 | $95K | Buy |
8,058
+1,074
| +15% | +$19.2K | ﹤0.01% | 6345 |
|
|
2021
Q4 | $227K | Sell |
6,984
-15,959
| -70% | -$646K | ﹤0.01% | 5999 |
|
|
2021
Q3 | $1.02M | Sell |
22,943
-17,391
| -43% | -$849K | ﹤0.01% | 5026 |
|
|
2021
Q2 | $2.2M | Buy |
40,334
+2,921
| +8% | +$173K | ﹤0.01% | 4554 |
|
|
2021
Q1 | $2.8M | Buy |
37,413
+29,834
| +394% | +$3.1M | ﹤0.01% | 3996 |
|
|
2020
Q4 | $822K | Buy |
7,579
+6,810
| +886% | +$621K | ﹤0.01% | 4773 |
|
|
2020
Q3 | $68K | Sell |
769
-1,596
| -67% | -$181K | ﹤0.01% | 5597 |
|
|
2020
Q2 | $252K | Buy |
2,365
+1,814
| +329% | +$163K | ﹤0.01% | 4970 |
|
|
2020
Q1 | $33K | Sell |
551
-4,586
| -89% | -$311K | ﹤0.01% | 5626 |
|
|
2019
Q4 | $355K | Buy |
5,137
+4,129
| +410% | +$250K | ﹤0.01% | 5118 |
|
|
2019
Q3 | $105K | Buy |
1,008
+883
| +706% | +$83.4K | ﹤0.01% | 5434 |
|
|
2019
Q2 | $12K | Sell |
125
-380
| -75% | -$26.5K | ﹤0.01% | 6086 |
|
|
2019
Q1 | $47K | Sell |
505
-3,417
| -87% | -$238K | ﹤0.01% | 5701 |
|
|
2018
Q4 | $218K | Sell |
3,922
-734
| -16% | -$55.8K | ﹤0.01% | 5249 |
|
|
2018
Q3 | $554K | Sell |
4,656
-794
| -15% | -$92.1K | ﹤0.01% | 4945 |
|
|
2018
Q2 | $556K | Buy |
5,450
+1,658
| +44% | +$205K | ﹤0.01% | 5028 |
|
|
2018
Q1 | $492K | Buy |
3,792
+1,078
| +40% | +$118K | ﹤0.01% | 5007 |
|
|
2017
Q4 | $265K | Buy |
2,714
+56
| +2% | +$7.52K | ﹤0.01% | 5307 |
|
|
2017
Q3 | $392K | Buy |
2,658
+1,198
| +82% | +$225K | ﹤0.01% | 5020 |
|
|
2017
Q2 | $235K | Buy |
1,460
+377
| +35% | +$59.2K | ﹤0.01% | 5250 |
|
|
2017
Q1 | $173K | Sell |
1,083
-2,021
| -65% | -$247K | ﹤0.01% | 5388 |
|
|
2016
Q4 | $377K | Sell |
3,104
-277
| -8% | -$38.8K | ﹤0.01% | 5080 |
|
|
2016
Q3 | $469K | Buy |
+3,381
| New | +$429K | ﹤0.01% | 4562 |
|
Other funds holding SYRS
BBA
1CM
XT
Morgan Stanley's SYRS Position: Q1 2025 in Review
Morgan Stanley sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 1,684 shares — an estimated $387 sold.
Morgan Stanley first reported a position in SYRS in Q3 2016 and held it in 34 quarters. The position peaked at $2.8M in Q1 2021. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Morgan Stanley reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Morgan Stanley sold 1,684 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $387.
- Morgan Stanley first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 34 quarters.
- Morgan Stanley's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.8M in Q1 2021.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.